By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cognition Therapeutics Inc. 

2403 Sidney Street
Suite 261
Pittsburgh  Pennsylvania  15203  U.S.A.
Phone: 412-481-2210 Fax: 412-481-2216



Company News
Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands To Board Of Directors 8/2/2017 10:23:22 AM
Cognition Therapeutics Reports Drug-Drug Interaction Results For CT1812, A Disease-Modifying Alzheimer’s Disease Candidate 7/19/2017 11:02:10 AM
Cognition Therapeutics Initiates US Clinical Testing Of CT1812, A Novel Small Molecule For The Potential Treatment Of Alzheimer's Disease 12/13/2016 7:22:21 AM
Cognition Therapeutics Sees Eli Lilly (LLY) Solanezumab Clinical Trial Results As Support For Its Unique Mechanism For Treatment Of Alzheimer's Disease 11/28/2016 6:59:13 AM
Cognition Therapeutics Announces Dosing Of First Alzheimer's Patient In Phase 1b Trial Of CT1812 11/14/2016 6:58:16 AM
Alzheimer's Biotech Cognition Therapeutics Taps Chimerix (CMRX)-Alteon (ALT) Vet as New CEO 10/28/2016 5:57:44 AM
Cognition Therapeutics Inc. Receives Michael J. Fox Foundation Grant To Study Inhibitors Of Alpha-Synuclein Oligomers For The Treatment Of Parkinson's Disease 9/29/2016 11:27:29 AM
Cognition Therapeutics Inc. Completes Oversubscribed $12 Million Series B Financing 9/8/2015 12:37:03 PM
Cognition Therapeutics Inc.Announces Publication Of Research Identifying Sigma-2/PGRMC1 Receptor As A Major New Drug Target For Alzheimer's Disease Therapy 11/13/2014 7:37:52 AM
Cognition Therapeutics Inc.'s Small Molecule Soluble Abeta Oligomer Receptor Antagonist Program For Alzheimer's Disease Selected For Support By National Institute on Aging/National Institutes of Health (NIH) Cooperative Agreement Program 5/22/2014 9:23:04 AM